Evidence map›Paper›PMID 32793210›Full record

ArticleFrontiers in immunology2020

Association of Country-Specific Socioeconomic Factors With Survival of Patients Who Experience Severe Classic Acute Graft-vs.-Host Disease After Allogeneic Hematopoietic Cell Transplantation. An Analysis From the Transplant Complications Working Party of the EBMT.

Andrzej Frankiewicz, Christophe Peczynski, Sebastian Giebel, Alenca Harrington, Gerard Socié, Dietger Niederwieser, Christoph Scheid, Martin Bornhäuser, Nicolaus Kröger, Ahmet Elmaagacli and 13 more

Open access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Increasing access to allogeneic hematopoietic cell transplant: an international perspective.Hematology. American Society of Hematology. Education Program · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 20 institutions in 5 countries.

Andrzej FrankiewiczThe Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Christophe PeczynskiEBMT Paris Study Office/CEREST-TC Hôpital Saint Antoine, Paris, France.
Sebastian GiebelThe Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.
Alenca HarringtonEBMT Paris Study Office/CEREST-TC Hôpital Saint Antoine, Paris, France.
Gerard SociéHopital St. Louis, Department of Hematology - BMT 1, Paris, France.
Dietger NiederwieserDivision of Hematology, Oncology and Hemostasiology, University Hospital Leipzig, Leipzig, Germany.
Christoph ScheidI. Department of Medicine, University of Cologne, Cologne, Germany.
Martin BornhäuserUniversitaetsklinikum Dresden Medizinische Klinik und Poliklinik, Dresden, Germany.
Nicolaus KrögerDepartment of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Ahmet ElmaagacliDepartment of Haematology, Asklepios Klinik St. Georg, Hamburg, Germany.
Boris AfanasyevRaisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, St. Petersburg, Russia.
Peter DregerUniversity of Heidelberg Medizinische Klinik und Poliklinik, Heidelberg, Germany.
Claudia RössigUniversitaetsklinikum Muenster Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie, Münster, Germany.
Didier BlaiseProgramme de Transplantation & Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille Institut Paoli Calmettes, Marseille, France.
Christian KratzDepartment of Pediatric Haematology/Oncology, Hannover Medical University, Hanover, Germany.
Ibrahim Yakoub-AghaHôpital HURIEZ UAM allo-CSH CHRU, Lille, France.
Bernhard KremensDepartment of Pediatric Hematology/Oncology, University Hospital, Essen, Germany.
Charlotte Marie NiemeyerPediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Centre, Freiburg, Germany.
Gerald WulfUniversitaetsklinikum Goettingen Abteilung Hämatologie und Onkologie, Gottingen, Germany.
Igor BlauDepartment of Hematology, Oncology and Tumorimmunology, Charite Universitätsmedizin Berlin, Berlin, Germany.
Olaf PenackDepartment of Hematology, Oncology and Tumorimmunology, Charite Universitätsmedizin Berlin, Berlin, Germany.
Hildegard GreinixKlinische Abteilung für Hämatologie, Universitätsklinik für Innere Medizin, Graz, Austria.
Grzegorz W BasakDepartment of Haematology, Oncology and Internal Medicine, Medical Uniwersity of Warsaw, Warsaw, Poland.
Charité - Universitätsmedizin Berlin · DEThe Maria Sklodowska-Curie National Research Institute of Oncology · PLAsklepios Klinik St. Georg · DECentre de Recherche en Cancérologie de Marseille · FREssen University Hospital · DEEuropean Society for Blood and Marrow Transplantation · FRFirst Pavlov State Medical University of St. Petersburg · RUHeidelberg University · DEHôpital Claude Huriez · FRHôpital Saint-Louis · FRKlinik und Poliklinik für Kinder- und Jugendmedizin · DEMedical University of Vienna · ATMedical University of Warsaw · PLMedizinische Hochschule Hannover · DESorbonne Université · FRUniversität Hamburg · DEUniversitätsmedizin Göttingen · DEUniversity Hospital Leipzig · DEUniversity Medical Center Freiburg · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute graft-vs.-host disease (aGvHD) is one of the most frequent causes of transplant-related mortality (TRM) after allogeneic hematopoietic cell transplantation (alloHCT). Its treatment is complex and costly. The aim of this study was to retrospectively analyze the impact of country-specific socioeconomic factors on outcome of patients who experience severe aGvHD. Adults with hematological malignancies receiving alloHCT from either HLA-matched siblings (

Indexed as

Acute DiseaseAdolescentAdultAgedDisease ProgressionEuropeFemaleGraft vs Host DiseaseHealth Care CostsHealth Care SurveysHematopoietic Stem Cell TransplantationHumansIncidenceMaleMiddle AgedMortalityacute graft-vs.-host diseasehealth care expenditurehematopoietic cell transplantationhuman development indextransplant-related mortality

Identifiers

PMID32793210
PMCPMC7390847
OpenAlexW3045414294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.